A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...

UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...

With the US capping inhaler prices at $35 ... “With Fasenra and Breztri, AstraZeneca is well-positioned to dominate the evolving COPD market. GlobalData projects that, if approved, Fasenra ...

With the US introducing a $35 inhaler price cap, competition between biologics and inhaled ... and improved outcomes are likely to capture a significant share of the moderate-to-severe COPD market ...

AstraZeneca’s other drugs, Fasenra, Calquence, Breztri and newer products, asthma drug Tezspire, breast cancer drug Truqap and lupus drug Saphnelo (anifrolumab) are likely to have contributed to ...

AstraZeneca’s recent presentation at the ... for half of the company’s total revenue by 2030. Key drivers include Breztri Aerosphere (budesonide, formoterol fumarate, and glycopyrrolate ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

like Breztri or Trelegy Ellipta). This group also includes SMART drugs like Symbicort (budesonide and formoterol fumarate dihydrate). Long-acting bronchodilators should not be used for an acute asthma ...

A young man with severe asthma used to be able to get his inhaler for cheap, but after UnitedHealthcare's drug arm jacked up the price, he had to go without — and it ultimately killed him ...